Emerging strategies to overcome resistance to third-generation EGFR inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Emerging strategies to overcome resistance to third-generation EGFR inhibitors ; volume:15 ; number:1 ; day:15 ; month:7 ; year:2022 ; pages:1-44 ; date:12.2022
Journal of hematology & oncology ; 15, Heft 1 (15.7.2022), 1-44, 12.2022
- Urheber
-
Shi, Kunyu
Wang, Guan
Pei, Junping
Zhang, Jifa
Wang, Jiaxing
Ouyang, Liang
Wang, Yuxi
Li, Weimin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-022-01311-6
- URN
-
urn:nbn:de:101:1-2022120213250722500933
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.07.20242025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shi, Kunyu
- Wang, Guan
- Pei, Junping
- Zhang, Jifa
- Wang, Jiaxing
- Ouyang, Liang
- Wang, Yuxi
- Li, Weimin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
Third-generation prospect theory
Third-generation prospect theory
Third-generation femtosecond technology